Pharmaceutical Systems Project Management Office
Pharmaceutical Systems Project Management Office (PSPMO)
MISSION: The mission of the Pharmaceutical Systems Project Management Office (PSPMO) is to develop and deliver vaccines, drugs, diagnostics, and hemorrhage control and resuscitation products to protect, treat, and sustain the health of our U.S. Service Members.
VISION: The Pharmaceutical Systems PMO serves the medical needs of our U.S. Service Members. We will advance their health and readiness through continually improving our acquisition strategies and by implementing innovative solutions to accelerate the development and fielding of medical products.
Pharmaceutical Systems PMO Focus Areas:
Pharmaceutical Systems PMO – Recent Success Stories:
Adenovirus vaccine is used by the Department of Defense to prevent adenovirus types 4- and 7- related acute respiratory disease in military recruits during basic training. Adenovirus infection in military recruits typically is manifested with pharyngitis, conjunctivitis, rhinitis and pneumonia during basic training. Adenoviruses can spread via direct contact and airborne and droplet transmission, and the close quarters combined with the stress of basic training, make recruits highly susceptible to exposure and infection. Prior to the availability of the vaccine, Adenovirus types 4 and 7 caused approximately 15,000 cases of acute respiratory diseases in recruits. Since the availability of the vaccine, the number of adenovirus respiratory diseases in recruits has decreased about 99 percent.
Leishmania Diagnostic Device:
The Leishmaniasis rapid diagnostic device is a field-deployable "dipstick" enabling the rapid diagnosis of cutaneous Leishmaniasis. This "point of care" test can detect within 30 minutes the presence of Leishmania parasites in samples taken from skin lesions.
High-quality microscopy to detect malaria parasites in blood is not always immediately available in every clinical setting where patients might seek medical attention. Binax NOW is a Rapid Diagnostic Test (RDT) to quickly (15 minutes) establish the diagnosis of malaria infection, allowing for accurate treatment and improved patient care. The test is an in vitro
immunochromatographic assay for the qualitative detection of Plasmodium
antigens circulating in human venous and capillary whole blood of individuals with signs and symptoms of malarial infection. The test targets a pan-malarial antigen common to all four malaria species capable of infecting humans - P. falciparum, P. vivax, P. ovale
, and P. malariae
back to top
Last Modified Date: 07/05/2018